^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
nilvanstomig (ZG005)
i
Other names: ZG005, ZG 005, ZG-005, GS14
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Suzhou Zelgen
Drug class:
PD1 inhibitor, TIGIT inhibitor
Related drugs:
3ms
Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=153, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P1/2 trial
|
nilvanstomig (ZG005)
4ms
Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma (clinicaltrials.gov)
P2, N=60, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P2 trial
|
cisplatin • gemcitabine • Tevimbra (tislelizumab-jsgr) • nilvanstomig (ZG005)
4ms
Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer (clinicaltrials.gov)
P1/2, N=120, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P1/2 trial
|
Avastin (bevacizumab) • nilvanstomig (ZG005)
5ms
ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma (clinicaltrials.gov)
P1/2, N=350, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P1/2 trial
|
alveltamig (ZG006) • nilvanstomig (ZG005)
8ms
Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=60, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P1/2 trial
|
ZGGS18 • nilvanstomig (ZG005)
8ms
Study of ZG005 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P2, N=100, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P2 trial
|
nilvanstomig (ZG005)
8ms
Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1/2, N=50, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P1/2 trial
|
nilvanstomig (ZG005)
9ms
Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma (clinicaltrials.gov)
P1/2, N=60, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P1/2 trial
|
nilvanstomig (ZG005)
12ms
Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
P2, N=90, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
Avastin (bevacizumab) • Tyvyt (sintilimab) • nilvanstomig (ZG005)
over1year
Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
P2, N=90, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P2 trial • Metastases
|
Avastin (bevacizumab) • Tyvyt (sintilimab) • nilvanstomig (ZG005)
over1year
A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor (clinicaltrials.gov)
P1/2, N=130, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
Zepsun (donafenib) • nilvanstomig (ZG005)
over1year
ZG005-004: Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma. (clinicaltrials.gov)
P1/2, N=93, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy • Metastases
|
cisplatin • etoposide IV • nilvanstomig (ZG005)
Share via
